Lexicon Pharmaceuticals (LXRX) Liabilities and Shareholders Equity (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $268.8 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $268.8 million, down 9.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $885.3 million (down 31.4% YoY), and the FY2025 annual result was $185.0 million, down 38.01% from the prior year.
• Liabilities and Shareholders Equity improved to $268.8 million in Q1 2026 per LXRX's latest filing, from $185.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $417.2 million in Q1 2024 and troughed at $112.3 million in Q2 2022.
• A 5-year average of $247.8 million and a median of $229.4 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity soared 181.97% in 2023, then sank 39.58% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $194.3 million in 2022, then rose by 18.08% to $229.4 million in 2023, then soared by 30.07% to $298.4 million in 2024, then sank by 38.01% to $185.0 million in 2025, then surged by 45.32% to $268.8 million in 2026.
• Business Quant data shows LXRX's Liabilities and Shareholders Equity at $268.8 million in Q1 2026, $185.0 million in Q4 2025, and $205.9 million in Q3 2025.